Parkinson'
Conditions
Interventions
Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days
Sponsors
StaGen Co. Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese patient who gave voluntary written consent with regard to study participation 2. Patient with 20 to 80 years of age 3. Gender: male or female 4. Patient who has been diagnosed with Parkinson's disease and fulfill all the following criteria, Hoehn-Yahr scale stage 1-3 MDS-UPDRS Part III score not less than 15 MMSE score not less than 24
Exclusion criteria
Exclusion criteria: (1) Patient who requires nearly full assistance in one's daily life, is incapable of walking and standing (2) Patient taking azathioprine, mercaptopurine hydrate, vidarabine or didanosine (3) Patient whose serum creatinine exceeds 1.5 times the upper limit of the reference value or whose AST (GOT) or ALT (GPT) exceeds the upper limit of the reference value in the pre-registration examination (4) Patient who has undergone surgical treatment for Parkinson's disease (5) Patient with a history or a current illness of gout, hyperuricaemia or urolithiasis (6) Patient who has been treated with febuxostat (7) Patient who has a history or a present illness of hypersensitivity / Idiosyncratic reaction (allergy) to a drug or drugs (8) Patient who has used an investigational drug within 30 days before the consent (9) Patient with pregnancy or a possibility of pregnancy, or lactating patient (10) Patient judged inappropriate with other reasons by a principal investigator or a subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference of MDS-UPDRS Part III score before registration and after 57 days of the treatment | — |
Countries
Japan
Contacts
Public ContactNaoyuki Kamatani
StaGen Co. Ltd. Research Institute for Artificial Intelligence in Medicine
Outcome results
None listed